Balance Sheet
Accumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CASI Pharmaceuticals (CASI) Total Debt (2021 - 2024)

Historic Total Debt for Pharmaceuticals (CASI) over the last 4 years, with Q4 2024 value amounting to $18.4 million.

  • Pharmaceuticals' Total Debt fell 9990.27% to $18.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $18.4 million, marking a year-over-year decrease of 9990.27%. This contributed to the annual value of $18.4 million for FY2024, which is 9990.27% down from last year.
  • Per Pharmaceuticals' latest filing, its Total Debt stood at $18.4 million for Q4 2024, which was down 9990.27% from $18.5 billion recorded in Q2 2024.
  • Pharmaceuticals' 5-year Total Debt high stood at $18.9 billion for Q4 2023, and its period low was $11.8 million during Q4 2022.
  • In the last 4 years, Pharmaceuticals' Total Debt had a median value of $18.5 million in 2024 and averaged $6.2 billion.
  • In the last 5 years, Pharmaceuticals' Total Debt surged by 15974265.29% in 2023 and then plummeted by 9990.27% in 2024.
  • Quarter analysis of 4 years shows Pharmaceuticals' Total Debt stood at $13.2 million in 2021, then decreased by 10.58% to $11.8 million in 2022, then surged by 159742.65% to $18.9 billion in 2023, then crashed by 99.9% to $18.4 million in 2024.
  • Its Total Debt was $18.4 million in Q4 2024, compared to $18.5 billion in Q2 2024 and $18.6 million in Q1 2024.